A Phase 3, Randomized, Double Blind, Placebo Control, Multicenter Study to Evaluate the Efficacy and Safety of TAK- 438 (10 and 20 mg Once-Daily) in Patients With Non-Erosive Gastroesophageal Reflux Disease.
Phase of Trial: Phase III
Latest Information Update: 23 May 2016
At a glance
- Drugs Vonoprazan (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Sponsors Takeda
- 21 Nov 2011 New trial record
- 01 Oct 2011 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.